JP2017532955A5 - - Google Patents

Download PDF

Info

Publication number
JP2017532955A5
JP2017532955A5 JP2017514521A JP2017514521A JP2017532955A5 JP 2017532955 A5 JP2017532955 A5 JP 2017532955A5 JP 2017514521 A JP2017514521 A JP 2017514521A JP 2017514521 A JP2017514521 A JP 2017514521A JP 2017532955 A5 JP2017532955 A5 JP 2017532955A5
Authority
JP
Japan
Prior art keywords
cell
genetically modified
zinc finger
modified cell
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017514521A
Other languages
English (en)
Japanese (ja)
Other versions
JP6722176B2 (ja
JP2017532955A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/050411 external-priority patent/WO2016044416A1/en
Publication of JP2017532955A publication Critical patent/JP2017532955A/ja
Publication of JP2017532955A5 publication Critical patent/JP2017532955A5/ja
Priority to JP2019150566A priority Critical patent/JP6929585B2/ja
Application granted granted Critical
Publication of JP6722176B2 publication Critical patent/JP6722176B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017514521A 2014-09-16 2015-09-16 造血幹細胞におけるヌクレアーゼ媒介性ゲノム工学および補正のための方法および組成物 Expired - Fee Related JP6722176B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019150566A JP6929585B2 (ja) 2014-09-16 2019-08-20 造血幹細胞におけるヌクレアーゼ媒介性ゲノム工学および補正のための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051159P 2014-09-16 2014-09-16
US62/051,159 2014-09-16
PCT/US2015/050411 WO2016044416A1 (en) 2014-09-16 2015-09-16 Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019150566A Division JP6929585B2 (ja) 2014-09-16 2019-08-20 造血幹細胞におけるヌクレアーゼ媒介性ゲノム工学および補正のための方法および組成物

Publications (3)

Publication Number Publication Date
JP2017532955A JP2017532955A (ja) 2017-11-09
JP2017532955A5 true JP2017532955A5 (cg-RX-API-DMAC7.html) 2018-08-16
JP6722176B2 JP6722176B2 (ja) 2020-07-15

Family

ID=55533790

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017514521A Expired - Fee Related JP6722176B2 (ja) 2014-09-16 2015-09-16 造血幹細胞におけるヌクレアーゼ媒介性ゲノム工学および補正のための方法および組成物
JP2019150566A Expired - Fee Related JP6929585B2 (ja) 2014-09-16 2019-08-20 造血幹細胞におけるヌクレアーゼ媒介性ゲノム工学および補正のための方法および組成物
JP2021128240A Pending JP2021182931A (ja) 2014-09-16 2021-08-04 造血幹細胞におけるヌクレアーゼ媒介性ゲノム工学および補正のための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019150566A Expired - Fee Related JP6929585B2 (ja) 2014-09-16 2019-08-20 造血幹細胞におけるヌクレアーゼ媒介性ゲノム工学および補正のための方法および組成物
JP2021128240A Pending JP2021182931A (ja) 2014-09-16 2021-08-04 造血幹細胞におけるヌクレアーゼ媒介性ゲノム工学および補正のための方法および組成物

Country Status (18)

Country Link
US (1) US10435677B2 (cg-RX-API-DMAC7.html)
EP (2) EP3878948A1 (cg-RX-API-DMAC7.html)
JP (3) JP6722176B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170054445A (cg-RX-API-DMAC7.html)
CN (2) CN113699113A (cg-RX-API-DMAC7.html)
AU (2) AU2015317793B2 (cg-RX-API-DMAC7.html)
CA (1) CA2960769A1 (cg-RX-API-DMAC7.html)
DK (1) DK3194570T3 (cg-RX-API-DMAC7.html)
ES (1) ES2886012T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20211468T1 (cg-RX-API-DMAC7.html)
HU (1) HUE055583T2 (cg-RX-API-DMAC7.html)
LT (1) LT3194570T (cg-RX-API-DMAC7.html)
PL (1) PL3194570T3 (cg-RX-API-DMAC7.html)
PT (1) PT3194570T (cg-RX-API-DMAC7.html)
RS (1) RS62334B1 (cg-RX-API-DMAC7.html)
SG (2) SG11201702134RA (cg-RX-API-DMAC7.html)
SI (1) SI3194570T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016044416A1 (cg-RX-API-DMAC7.html)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2853829C (en) 2011-07-22 2023-09-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US20150166982A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting pi3k point mutations
EP3177718B1 (en) 2014-07-30 2022-03-16 President and Fellows of Harvard College Cas9 proteins including ligand-dependent inteins
JP7030522B2 (ja) * 2015-05-11 2022-03-07 エディタス・メディシン、インコーポレイテッド 幹細胞における遺伝子編集のための最適化crispr/cas9システムおよび方法
MX382223B (es) * 2015-05-12 2025-03-13 Sangamo Therapeutics Inc Regulacion de expresion genica mediada por nucleasa.
KR102796744B1 (ko) 2015-06-09 2025-04-15 에디타스 메디신, 인코포레이티드 이식의 개선을 위한 crispr/cas-관련 방법 및 조성물
GB2592821B (en) 2015-07-31 2022-01-12 Univ Minnesota Modified cells and methods of therapy
WO2017053729A1 (en) 2015-09-25 2017-03-30 The Board Of Trustees Of The Leland Stanford Junior University Nuclease-mediated genome editing of primary cells and enrichment thereof
SG11201803173VA (en) 2015-10-23 2018-05-30 Harvard College Nucleobase editors and uses thereof
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2017214569A1 (en) * 2016-06-09 2017-12-14 Regents Of The University Of Minnesota Genome-edited nk cell and methods of making and using
JP7231935B2 (ja) 2016-08-03 2023-03-08 プレジデント アンド フェローズ オブ ハーバード カレッジ アデノシン核酸塩基編集因子およびそれらの使用
CA3033327A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
WO2018071868A1 (en) 2016-10-14 2018-04-19 President And Fellows Of Harvard College Aav delivery of nucleobase editors
AU2017382171A1 (en) * 2016-12-19 2019-07-04 The Uab Research Foundation Mass spectrometric standards for hemoglobin beta and hemoglobin beta sickle and uses thereof
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
AU2018212652B2 (en) * 2017-01-26 2024-03-28 Sangamo Therapeutics, Inc. B-cell engineering
JP7175277B2 (ja) 2017-01-27 2022-11-18 チルドレンズ ホスピタル メディカル センター 造血幹細胞の生着活性を向上させる方法
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
US11975029B2 (en) 2017-02-28 2024-05-07 Vor Biopharma Inc. Compositions and methods for inhibition of lineage specific proteins
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
JP2020518245A (ja) 2017-05-03 2020-06-25 サンガモ セラピューティクス, インコーポレイテッド 嚢胞性線維症膜貫通コンダクタンス制御因子(cftr)遺伝子の改変のための方法および組成物
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
AU2018352592C1 (en) 2017-10-16 2025-09-25 Beam Therapeutics, Inc. Uses of adenosine base editors
CN109722414A (zh) * 2017-10-27 2019-05-07 博雅辑因(北京)生物科技有限公司 一种高效制备成熟红细胞的方法以及用于制备成熟红细胞的培养基
CA3079405A1 (en) * 2017-10-31 2019-05-09 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
JP2021502085A (ja) * 2017-11-09 2021-01-28 サンガモ セラピューティクス, インコーポレイテッド サイトカイン誘導性sh2含有タンパク質(cish)遺伝子の遺伝子改変
EP3724214A4 (en) 2017-12-15 2021-09-01 The Broad Institute Inc. SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING
EP3511412A1 (en) * 2018-01-12 2019-07-17 Genethon Genetically engineered hematopoietic stem cell as a platform for systemic protein expression
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
EP3575402A1 (en) * 2018-06-01 2019-12-04 Algentech SAS Gene targeting
SG11202101576UA (en) 2018-08-18 2021-03-30 Harvard College In situ gene editing
WO2020046951A1 (en) * 2018-08-27 2020-03-05 The Regents Of The University Of California Methods to control viral infection in mammalian cells
CN113423725A (zh) 2018-08-28 2021-09-21 Vor生物制药股份有限公司 遗传工程化造血干细胞及其用途
GB201815670D0 (en) * 2018-09-26 2018-11-07 Univ Oxford Innovation Ltd Protein editing
US12281338B2 (en) 2018-10-29 2025-04-22 The Broad Institute, Inc. Nucleobase editors comprising GeoCas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
US20220177922A1 (en) * 2019-03-07 2022-06-09 National University Corporation Tokyo Medical And Dental University High-throughput gene-editing technique
GB2601617B (en) 2019-03-19 2024-02-21 Broad Inst Inc Methods and compositions for editing nucleotide sequences
JP2022519949A (ja) 2019-04-02 2022-03-25 サンガモ セラピューティクス, インコーポレイテッド ベータ-サラセミアの治療のための方法
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
EP3958879A4 (en) * 2019-04-25 2023-05-10 Actinium Pharmaceuticals, Inc. Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases
EP3770264A1 (en) * 2019-07-22 2021-01-27 Genethon Precise integration using nuclease targeted idlv
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
US20240124561A1 (en) * 2019-10-17 2024-04-18 Minicircle Inc. Nucleic acids encoding hiv neutralizing antibodies and uses thereof
DE112021002672T5 (de) 2020-05-08 2023-04-13 President And Fellows Of Harvard College Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
WO2022094363A1 (en) * 2020-11-01 2022-05-05 University of South Alabama Foundation for Research and Commercialization Barcoded cells engineered with heterozygous genetic diversity
CN115232811B (zh) * 2021-06-28 2025-10-28 南京启真基因工程有限公司 用于构建hbb基因突变的镰刀型细胞贫血症模型猪核移植供体细胞的方法及应用
US20240309361A1 (en) * 2021-07-01 2024-09-19 Bluebird Bio, Inc. Methods
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025194138A1 (en) 2024-03-14 2025-09-18 Tessera Therapeutics, Inc. St1cas9 compositions and methods for modulating a genome
WO2025194124A1 (en) 2024-03-14 2025-09-18 Tessera Therapeutics, Inc. Modified st1cas9 guide nucleic acids

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US5422251A (en) 1986-11-26 1995-06-06 Princeton University Triple-stranded nucleic acids
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6242568B1 (en) 1994-01-18 2001-06-05 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
AU704601B2 (en) 1994-01-18 1999-04-29 Scripps Research Institute, The Zinc finger protein derivatives and methods therefor
AU696455C (en) 1994-03-23 2006-03-02 Case Western Reserve University Compacted nucleic acids and their delivery to cells
US5585245A (en) 1994-04-22 1996-12-17 California Institute Of Technology Ubiquitin-based split protein sensor
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
USRE39229E1 (en) 1994-08-20 2006-08-08 Gendaq Limited Binding proteins for recognition of DNA
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
ATE318327T1 (de) * 1996-06-04 2006-03-15 Univ Utah Res Found Fluoreszenz-donor-akzeptor paar
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
GB2338237B (en) 1997-02-18 2001-02-28 Actinova Ltd In vitro peptide or protein expression library
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
US6342345B1 (en) 1997-04-02 2002-01-29 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by reporter subunit complementation
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
US6479626B1 (en) 1998-03-02 2002-11-12 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
EP1236045B1 (en) 1999-12-06 2005-11-09 Sangamo Biosciences Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
CA2398590C (en) 2000-02-08 2012-08-28 Sangamo Biosciences, Inc. Cells for drug discovery
US20020061512A1 (en) 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
WO2001088197A2 (en) 2000-05-16 2001-11-22 Massachusetts Institute Of Technology Methods and compositions for interaction trap assays
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US20050267061A1 (en) 2004-04-08 2005-12-01 Sangamo Biosciences, Inc. Methods and compositions for treating neuropathic and neurodegenerative conditions
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
US7030846B2 (en) 2001-07-10 2006-04-18 Samsung Electronics Co., Ltd. Color correction liquid crystal display and method of driving same
WO2003016496A2 (en) 2001-08-20 2003-02-27 The Scripps Research Institute Zinc finger binding domains for cnn
EP2266396A3 (en) 2001-09-24 2011-06-15 Sangamo BioSciences, Inc. Modulation of stem cells using zinc finger proteins
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
JP4968498B2 (ja) 2002-01-23 2012-07-04 ユニバーシティ オブ ユタ リサーチ ファウンデーション ジンクフィンガーヌクレアーゼを用いる、標的化された染色体変異誘発
EP2368982A3 (en) 2002-03-21 2011-10-12 Sangamo BioSciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
US9447434B2 (en) 2002-09-05 2016-09-20 California Institute Of Technology Use of chimeric nucleases to stimulate gene targeting
AU2003261970A1 (en) * 2002-09-06 2004-03-29 Wakunaga Pharmaceutical Co., Ltd. Method of identifying nucleic acid having polymorphism sequence site
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
CA2562193A1 (en) 2004-04-08 2005-10-27 Sangamo Biosciences, Inc. Treatment of neuropathic pain with zinc finger proteins
CA2579677A1 (en) 2004-09-16 2006-03-30 Sangamo Biosciences, Inc. Compositions and methods for protein production
MX2007013757A (es) 2005-05-05 2008-01-24 Univ Arizona Reagrupacion permitida de secuencia (seer)-met odo de novedad para visualizar secuencias de adn especificas.
JP5139271B2 (ja) 2005-05-24 2013-02-06 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ 培養した造血幹細胞を拡大しかつ分析する方法
SG10201508995QA (en) 2005-07-26 2015-11-27 Sangamo Biosciences Inc Targeted integration and expression of exogenous nucleic acid sequences
ES2533370T3 (es) 2005-10-18 2015-04-09 Precision Biosciences Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
EP1999255A2 (en) 2006-03-24 2008-12-10 The Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
EP2765195A1 (en) 2006-05-25 2014-08-13 Sangamo BioSciences, Inc. Methods and compositions for gene inactivation
ATE462783T1 (de) 2006-05-25 2010-04-15 Sangamo Biosciences Inc Variante foki-spaltungshälften-domänen
DE602008003684D1 (de) 2007-04-26 2011-01-05 Sangamo Biosciences Inc Gezielte integration in die ppp1r12c-position
US8790345B2 (en) 2007-08-21 2014-07-29 Zimmer, Inc. Titanium alloy with oxidized zirconium for a prosthetic implant
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
EP2281050B1 (en) 2008-04-14 2014-04-02 Sangamo BioSciences, Inc. Linear donor constructs for targeted integration
CA2734235C (en) 2008-08-22 2019-03-26 Sangamo Biosciences, Inc. Methods and compositions for targeted single-stranded cleavage and targeted integration
ES2561599T3 (es) 2008-08-28 2016-02-29 Taiga Biotechnologies, Inc. Moduladores de MYC, métodos de uso de los mismos, y métodos para identificar agentes que modulan MYC
WO2010065123A1 (en) 2008-12-04 2010-06-10 Sangamo Biosciences, Inc. Genome editing in rats using zinc-finger nucleases
CA2747124C (en) 2008-12-17 2018-09-04 Dow Agrosciences Llc Targeted integration into the zp15 locus
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
MX336846B (es) * 2010-01-22 2016-02-03 Sangamo Biosciences Inc Alteracion genomica dirigida.
EP2615106B1 (en) 2010-02-08 2018-04-25 Sangamo Therapeutics, Inc. Engineered cleavage half-domains
AU2011215557B2 (en) 2010-02-09 2016-03-10 Sangamo Therapeutics, Inc. Targeted genomic modification with partially single-stranded donor molecules
WO2011139336A1 (en) 2010-04-26 2011-11-10 Sangamo Biosciences, Inc. Genome editing of a rosa locus using nucleases
EP2571512B1 (en) 2010-05-17 2017-08-23 Sangamo BioSciences, Inc. Novel dna-binding proteins and uses thereof
US8945868B2 (en) 2010-07-21 2015-02-03 Sangamo Biosciences, Inc. Methods and compositions for modification of a HLA locus
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
EP2643454A4 (en) 2010-11-24 2014-05-21 Hong Gao EXPANSION OF HEMATOPOETIC STEM CELLS
WO2013019745A1 (en) 2011-07-29 2013-02-07 Georgia Health Sciences University Methods and compositions for genetically modifiying cells
IL293650B2 (en) 2011-09-21 2024-10-01 Sangamo Therapeutics Inc Methods and compositions for regulation of transgene expression
AU2012328682B2 (en) 2011-10-27 2017-09-21 Sangamo Therapeutics, Inc. Methods and compositions for modification of the HPRT locus
RU2018109507A (ru) 2012-02-24 2019-02-28 Фред Хатчинсон Кэнсер Рисерч Сентер Композиции и способы лечения гемоглобинопатии
US10174331B2 (en) * 2012-05-07 2019-01-08 Sangamo Therapeutics, Inc. Methods and compositions for nuclease-mediated targeted integration of transgenes
WO2013169398A2 (en) * 2012-05-09 2013-11-14 Georgia Tech Research Corporation Systems and methods for improving nuclease specificity and activity
CA2878037C (en) * 2012-07-11 2021-08-31 Sangamo Biosciences, Inc. Methods and compositions for delivery of biologics
CN114645015A (zh) 2012-07-20 2022-06-21 泰加生物工艺学公司 造血区室的增强的重建和自动重建
SG11201500852WA (en) * 2012-08-29 2015-04-29 Sangamo Biosciences Inc Methods and compositions for treatment of a genetic condition
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
WO2014186585A2 (en) 2013-05-15 2014-11-20 Sangamo Biosciences, Inc. Methods and compositions for treatment of a genetic condition
BR112016025849A2 (pt) 2014-05-08 2017-10-17 Chdi Foundation Inc métodos e composições para o tratamento da doença de huntington

Similar Documents

Publication Publication Date Title
JP2017532955A5 (cg-RX-API-DMAC7.html)
JP7252328B2 (ja) Rnaを編集する方法および組成物
ES2942309T3 (es) Materiales y métodos para el tratamiento de hemoglobinopatías
HRP20211468T1 (hr) Postupci i pripravci za nukleazno posredovani inženjering genoma i ispravak u krvotvornim matičnim stanicama
AU2016225178B2 (en) Materials and methods for treatment of hemoglobinopathies
AU2019236209A1 (en) Systems and methods for the treatment of hemoglobinopathies
HRP20190825T1 (hr) Regulacija genske ekspresije posredovana nukleazama
WO2018170184A1 (en) Systems and methods for the treatment of hemoglobinopathies
JP2019508051A5 (cg-RX-API-DMAC7.html)
CN111278976A (zh) 一种提高胎儿血红蛋白表达的方法
MY203407A (en) Compositions and methods for the treatment of hemoglobinopathies
JP2015533786A5 (cg-RX-API-DMAC7.html)
HRP20212025T1 (hr) Regulacija ekspresije gena pomoću projektiranih nukleaza
RU2020104969A (ru) Способы и продукты для получения и доставки нуклеиновых кислот
CN109689865A (zh) Bcl11a归巢核酸内切酶变体、组合物和使用方法
EP3765617A1 (en) Systems and methods for the treatment of hemoglobinopathies
WO2022000572A1 (zh) 激活γ-珠蛋白基因表达的方法和组合物
WO2020113112A1 (en) Systems and methods for the treatment of hemoglobinopathies
US20240181005A1 (en) Compositions, systems, and methods for generating gene-edited cells
AU2019230210A1 (en) Systems and methods for the treatment of hemoglobinopathies
US20240139254A1 (en) Mesenchymal stem cell having oxidative stress resistance, preparation method therefor, and use thereof
WO2018200597A1 (en) Homology directed repair compositions for the treatment of hemoglobinopathies
Guan et al. Application of CRISPR-Cas system in gene therapy: pre-clinical progress in animal model
DeWitt et al. Efficient correction of the sickle mutation in human hematopoietic stem cells using a Cas9 ribonucleoprotein complex
JP7416745B2 (ja) 改変細胞、調製方法、及び構築物